Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized TSH suppression therapy for differentiated thyroid cancer
ChiCTR2200055711Phase 4Recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in papillary thyroid cancer (PTC) and well-differentiated thyroid cancer (WDTC) comparing Experiment group: thyroid tablets + levothyroxine with Control group: levothyroxine (2 arms). Primary endpoint: Clinical effective rate. Started Feb 2022; status: recruiting.
02
Drugs
levothyroxine sodiumthyroid, porcine
03
Conditions
papillary thyroid cancer (PTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2200055711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055711.